About us

Novo Nordisk Pharmatech A/S is a pharmaceutical company and was established in 1949 as FeF Chemicals. In 1986 FeF Chemicals was acquired by Novo Nordisk, a world leader in diabetes care and a Danish healthcare company. Novo Nordisk Pharmatech has since then been part of the Novo Nordisk pharmaceutical group.

Novo Nordisk Pharmatech A/S is the leading worldwide supplier of products as recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the biopharmaceutical and pharmaceutical industries. We improve biopharmaceutical manufacturing by developing and supplying innovative products used in the manufacturing of biopharmaceuticals.

We as a company has attracted the leading pharmaceutical companies through our high product quality, extensive manufacturing and quality control, regulatory documentation, precision delivery and a comprehensive risk mitigation strategy.

Securing your end-to-end supply chain

Our history

Company 1


Facts & figures


Our mission & vision


Enabling better medicines.


We are committed to providing sustainable pharmaceutical materials through innovative and customised solutions

Novo Nordisk - Pharmatech - Benzalkonium chloride

We are global

Company 3

Novo Nordisk Pharmatech is currently present in the following:

  • Headquarter & manufacturing exclusively in Denmark
  • Branch office in Singapore
  • Branch office in Boston, USA
  • Distribution center in Indianapolis, USA


Corporate movie

Get a short introduction to Novo Nordisk Pharmatech.

The Novo Nordisk Way

About Us_Test 7

The Novo Nordisk Way is a set of guiding principles which underpins every decision we make.  It describes who we are, how we work and what we want to achieve, and sets a clear direction for our company and our employees. Ultimately, it’s a promise we make to each other – and to the millions of patients all over the world who rely on our products to lead full and healthy lives.

In 1923, our Danish founders began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, skills and commitment to drive change to defeat diabetes and other serious chronic diseases.

  • We aim to lead in all disease areas in which we are active.
  • Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
  • Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.
  • Our business philosophy is one of balancing financial, social and environmental considerations – we call it ‘The Triple Bottom Line’.
  • We are open and honest, ambitious and accountable, and treat everyone with respect.
  • We offer opportunities for our people to realise their potential.
  • We never compromise on quality and business ethics.

Every day, we must make difficult choices, always keeping in mind what is best for patients, our employees and our shareholders in the long run.

It’s our way. It’s the Novo Nordisk Way.

Annual report 2021_front

Annual report

Our company

Contact us